INS and type 2 diabetes mellitus: Inhibition of DPP‐4 activity specifically results in higher glucagon‐like peptide‐1 levels, and increases the half‐life of circulating insulin, thereby enhancing glycemic control in individuals with type 2 diabetes (Tasyurek et al. 2014).